MTV273

P1, N=40, Active, not recruiting, University of Pennsylvania | Trial primary completion date: May 2022 --> Mar 2036

P1, N=40, Active, not recruiting, University of Pennsylvania | Trial primary completion date: May 2021 --> May 2022

Study intervention in this clinical trial consisted of 4 cycles of bortezomib-based induction treatment followed stem cell mobilization by cyclophosphamide 3 g/m2...The median PFS and OS of the patients in two groups were all not reached but 21-months PFS was 73% and 55% for two groups respectively (p<0.05); 21-months OS was 100% and 61% for each group (p<0.05) (Figure 1). Conclusion Combined infusion of anti-CD19 and anti-BCMA CART cells after ASCT for high risk MM was safe and effective, and can significantly prolong the PFS and OS compared to single ASCT.

After one month from CARTs infusion, some pts were adminstrated IMiDs for maintence therapy after hematopoietic recovery, including oral thalidomide 50mg/d or lenalidomide 10mg/d... Combined sequential administration of CART-19 and CART-BCMA cells can be manufactured from heavily-treated MM pts, and could elicit sustained remission for RRMM pts. Toxicities can be well tolerated. CARTs early expansion and persistence in vivo post infusion may be predictive of clinical outcome.